LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 142

Search options

  1. Book ; Online: Cannabis : Neuropsychiatry and Its Effects on Brain and Behavior

    Colizzi, Marco / Bhattacharyya, Sagnik

    2021  

    Keywords Medicine ; Neurosciences ; delta-9-tetrahydrocannabinol ; placebo ; cannabis-associated psychosis ; schizophrenia ; BDNF ; CB1 ; CB2 ; episodic memory ; exercise ; African American ; black ; older adult ; marijuana use ; cannabis use disorder ; cue reactivity ; craving ; inhibitory control ; frontal alpha asymmetry ; EEG ; cannabinoids ; cannabis use ; psychotic disorder ; genetics ; age of onset ; clinical high risk ; cannabis ; memory ; functional magnetic resonance imaging ; THC ; systematic review ; gyrification ; surface area ; cortical surface structure ; aerobic fitness ; gender ; endocannabinoid system ; executive functions ; problematic cannabis use ; triple network ; EEG functional connectivity ; eLORETA ; resting state ; Delta-9-tetrahydrocannabinol ; dronabinol ; marijuana ; randomized controlled trial ; opioids ; traumatic injury ; alcohol ; adolescents ; fMRI ; interoception ; negative reinforcement ; migraine: chronic pain ; triptans ; disability ; n/a
    Size 1 electronic resource (204 pages)
    Publisher MDPI - Multidisciplinary Digital Publishing Institute
    Publishing place Basel, Switzerland
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021044593
    ISBN 9783039439966 ; 3039439960
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  2. Article ; Online: Association of Medication Nonadherence With Increased Risk of Violence to Others Among Patients With Schizophrenia.

    Bhattacharyya, Sagnik

    JAMA network open

    2023  Volume 6, Issue 4, Page(s) e235784

    MeSH term(s) Humans ; Schizophrenia/drug therapy ; Medication Adherence ; Antipsychotic Agents/therapeutic use ; Patients ; Violence
    Chemical Substances Antipsychotic Agents
    Language English
    Publishing date 2023-04-03
    Publishing country United States
    Document type Journal Article ; Comment
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2023.5784
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Cognitive and executive impairments in Parkinson's disease psychosis: a Bayesian meta-analysis.

    Pisani, Sara / Gosse, Luca / Wieretilo, Rita / Ffytche, Dominic / Velayudhan, Latha / Bhattacharyya, Sagnik

    Journal of neurology, neurosurgery, and psychiatry

    2024  Volume 95, Issue 3, Page(s) 277–287

    Abstract: Background: Cognitive and executive deficits lead to worsening of quality of life and are a risk factor for developing dementia in people with Parkinson's disease (PD) with psychosis (PDP). However, which key cognitive domains are differentially ... ...

    Abstract Background: Cognitive and executive deficits lead to worsening of quality of life and are a risk factor for developing dementia in people with Parkinson's disease (PD) with psychosis (PDP). However, which key cognitive domains are differentially affected in PDP compared with those without (PDnP), remains unclear. Here, we examined this using a Bayesian meta-analytical approach.
    Methods: Searches were conducted on PubMed, Web of Science, SCOPUS, Medline and PsycINFO. Hedges' g effect-size estimates were extracted from eligible studies as a measure of standard mean differences between PDP and PDnP participants. Meta-analyses were conducted separately for each cognitive domain and subdomain, we examined the effect of age, PD medications, PD duration and severity, depression and psychosis severity for all major domains with meta-regressions.
    Results: Effect-size estimates suggest worse performance on all major domains (k=105 studies) in PDP compared with PDnP participants, with global cognition (k=103 studies, g=-0.57), processing speed (k=29 studies, g=-0.58), executive functions (k=33, g=-0.56), episodic memory (k=30 studies, g=-0.58) and perception (k=34 studies, g=-0.55) as the most likely affected domains. Age, depression and PD duration had moderating effects on task-related performance across most of the major nine domains.
    Conclusions: We report extensive deficits across nine domains as well as subdomains in PD psychosis, with global cognition, processing speed and executive functions as the most likely impaired. The presence of depression may influence task-related performance in PDP, alongside age and PD duration, but not dose of dopamine replacement treatments.
    MeSH term(s) Humans ; Parkinson Disease/complications ; Parkinson Disease/psychology ; Quality of Life ; Bayes Theorem ; Cognition ; Executive Function ; Psychotic Disorders/complications ; Cognitive Dysfunction/etiology ; Organophosphorus Compounds
    Chemical Substances phenyl di-n-pentylphosphinate (14656-17-8) ; Organophosphorus Compounds
    Language English
    Publishing date 2024-02-14
    Publishing country England
    Document type Meta-Analysis ; Journal Article
    ZDB-ID 3087-9
    ISSN 1468-330X ; 0022-3050
    ISSN (online) 1468-330X
    ISSN 0022-3050
    DOI 10.1136/jnnp-2022-331028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Cannabidiol for behavior symptoms in Alzheimer's disease (CANBiS-AD): a randomized, double-blind, placebo-controlled trial.

    Velayudhan, Latha / Dugonjic, Marta / Pisani, Sara / Harborow, Lucy / Aarsland, Dag / Bassett, Paul / Bhattacharyya, Sagnik

    International psychogeriatrics

    2024  , Page(s) 1–3

    Language English
    Publishing date 2024-04-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 1038825-4
    ISSN 1741-203X ; 1041-6102
    ISSN (online) 1741-203X
    ISSN 1041-6102
    DOI 10.1017/S1041610224000516
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Is It Time to Test the Antiseizure Potential of Palmitoylethanolamide in Human Studies? A Systematic Review of Preclinical Evidence.

    Bortoletto, Riccardo / Balestrieri, Matteo / Bhattacharyya, Sagnik / Colizzi, Marco

    Brain sciences

    2022  Volume 12, Issue 1

    Abstract: Antiseizure medications are the cornerstone pharmacotherapy for epilepsy. They are not devoid of side effects. In search for better-tolerated antiseizure agents, cannabinoid compounds and other N-acylethanolamines not directly binding cannabinoid ... ...

    Abstract Antiseizure medications are the cornerstone pharmacotherapy for epilepsy. They are not devoid of side effects. In search for better-tolerated antiseizure agents, cannabinoid compounds and other N-acylethanolamines not directly binding cannabinoid receptors have drawn significant attention. Among these, palmitoylethanolamide (PEA) has shown neuroprotective, anti-inflammatory, and analgesic properties. All studies examining PEA's role in epilepsy and acute seizures were systematically reviewed. Preclinical studies indicated a systematically reduced PEA tone accompanied by alterations of endocannabinoid levels. PEA supplementation reduced seizure frequency and severity in animal models of epilepsy and acute seizures, in some cases, similarly to available antiseizure medications but with a better safety profile. The peripheral-brain immune system seemed to be more effectively modulated by subchronic pretreatment with PEA, with positive consequences in terms of better responding to subsequent epileptogenic insults. PEA treatment restored the endocannabinoid level changes that occur in a seizure episode, with potential preventive implications in terms of neural damage. Neurobiological mechanisms for PEA antiseizure effect seemed to include the activation of the endocannabinoid system and the modulation of neuroinflammation and excitotoxicity. Although no human study was identified, there is ground for testing the antiseizure potential of PEA and its safety profile in human studies of epilepsy.
    Language English
    Publishing date 2022-01-12
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2651993-8
    ISSN 2076-3425
    ISSN 2076-3425
    DOI 10.3390/brainsci12010101
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Cannabis: Neuropsychiatry and Its Effects on Brain and Behavior.

    Colizzi, Marco / Bhattacharyya, Sagnik

    Brain sciences

    2020  Volume 10, Issue 11

    Abstract: Possibly orally transmitted from before circa 2000 B [ ... ]. ...

    Abstract Possibly orally transmitted from before circa 2000 B [...].
    Language English
    Publishing date 2020-11-10
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2651993-8
    ISSN 2076-3425
    ISSN 2076-3425
    DOI 10.3390/brainsci10110834
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Cannabis use-related working memory deficit mediated by lower left hippocampal volume.

    Paul, Subhadip / Bhattacharyya, Sagnik

    Addiction biology

    2020  Volume 26, Issue 4, Page(s) e12984

    Abstract: The association between cannabis exposure and working memory impairment and its neural substrates remain unclear. In this cross-sectional observational study, we investigated this by examining the relationship between frequency of exposure to cannabis, ... ...

    Abstract The association between cannabis exposure and working memory impairment and its neural substrates remain unclear. In this cross-sectional observational study, we investigated this by examining the relationship between frequency of exposure to cannabis, working memory performance and regional brain volumes and tested whether lower volumes of cortical and subcortical structures mediate the association between cannabis exposure and working memory deficit using the Human Connectome Project data from 234 individuals with self-reported cannabis exposure and 174 individuals unexposed to cannabis. We tested the relationship between self-reported frequency of cannabis exposure and list-sorting working memory task performance (total number of correct responses), between T1 weighted MRI-derived regional grey-matter volumes and working memory task performance as well as between frequency of cannabis exposure and brain volumes after controlling for potential confounders. Finally, mediation analysis was carried out to test whether deficit in working memory performance associated with cannabis use was mediated by its association with lower grey-matter volume. Participants who reported higher frequency of cannabis use tended to have lower number of correct responses in the list-sorting working memory task and lower bilateral hippocampal volumes. Association between severity of cannabis exposure as indexed by frequency of cannabis use and impairment in working memory was mediated by lower left hippocampal volume in cannabis users. We report evidence in support of the left hippocampus volume-mediated working memory impairment associated with recreational cannabis exposure. Future studies employing prospective longitudinal design are necessary to examine the cause-effect relationships of cannabis exposure on working memory and brain volumes.
    MeSH term(s) Adolescent ; Adult ; Cannabis ; Cross-Sectional Studies ; Female ; Gray Matter/drug effects ; Hippocampus/physiopathology ; Humans ; Magnetic Resonance Imaging ; Male ; Marijuana Use/adverse effects ; Mediation Analysis ; Memory Disorders/etiology ; Memory, Short-Term/drug effects ; Young Adult
    Language English
    Publishing date 2020-11-05
    Publishing country United States
    Document type Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 1324314-7
    ISSN 1369-1600 ; 1355-6215
    ISSN (online) 1369-1600
    ISSN 1355-6215
    DOI 10.1111/adb.12984
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Are researchers getting the terms used to denote different types of recreational cannabis right?-a user perspective.

    Mason, Ava / Sami, Musa / Notley, Caitlin / Bhattacharyya, Sagnik

    Journal of cannabis research

    2021  Volume 3, Issue 1, Page(s) 12

    Abstract: Background: While current cannabis research has advanced our understanding into the effects of its individual components, there is a pressing need to identify simple terminology that is understood in the same way by researchers and users of cannabis. ... ...

    Abstract Background: While current cannabis research has advanced our understanding into the effects of its individual components, there is a pressing need to identify simple terminology that is understood in the same way by researchers and users of cannabis. Current categorisation in research focuses on the two main cannabinoids: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD); and two different species of cannabis: indica and sativa. Recreational cannabis has also been categorised by researchers as 'skunk' or 'hash'. Focusing on individuals who use cannabis frequently, this study aimed to identify views on current terms used to denote different types of cannabis and to identify terms validated by participants. These views were extracted from responses of the Cannabis Experiences Questionnaire (CEQ), a widely used instrument in the literature.
    Methods: We qualitatively analysed 236 free-text responses from Question 23 of the CEQ survey (using Iterative Categorisation) relating to categorization and consumption methods. Data was used from a previous study (Sami et al., Psychol Med 49:103-12, 2019), which recruited a convenience sample of 1231 participants aged 18 years and above who had previously used cannabis.
    Results: Regarding type of cannabis used, specific strain names (n = 130), concentrates (n = 37), indica/sativa (n = 22) and THC/CBD terms (n = 22) were mentioned. Other terms used were hybrids (n = 10), origins of specific strains (n = 17), edibles (n = 8), and herbal cannabis (n = 7). Regarding problems with specific terms, participants were skeptical about terms such as skunk and super skunk (n = 78) preferring terms like THC/CBD, indica/sativa, specific marketed strains and references to preparation methods.
    Conclusions: The results suggest a disparity between the common terms used by researchers in academia and those used by cannabis consumers. While there are advantages and limitations of using these terms to bridge views of researchers and individuals who use cannabis, this study underscores the importance of formally assessing chemical constituents rather than relying on self-report data and of incorporating cannabis user views on current terms used in research, potentially also incorporating descriptors of preparation and consumption methods.
    Language English
    Publishing date 2021-04-29
    Publishing country England
    Document type Journal Article
    ISSN 2522-5782
    ISSN (online) 2522-5782
    DOI 10.1186/s42238-021-00065-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis.

    Velayudhan, Latha / McGoohan, Katie Louise / Bhattacharyya, Sagnik

    JAMA network open

    2021  Volume 4, Issue 2, Page(s) e2035913

    MeSH term(s) Aged ; Anorexia/chemically induced ; Anorexia/drug therapy ; Antineoplastic Agents/adverse effects ; Cancer Pain/drug therapy ; Cannabidiol/adverse effects ; Cannabinoid Receptor Agonists/adverse effects ; Cannabinoids/adverse effects ; Dizziness/chemically induced ; Dose-Response Relationship, Drug ; Dronabinol/adverse effects ; Dronabinol/analogs & derivatives ; Humans ; Middle Aged ; Multiple Sclerosis/drug therapy ; Nausea/chemically induced ; Nausea/drug therapy ; Neurodegenerative Diseases/drug therapy ; Pain/drug therapy ; Perceptual Disorders/chemically induced ; Randomized Controlled Trials as Topic ; Regression Analysis ; Self Report ; Vomiting/chemically induced ; Vomiting/drug therapy
    Chemical Substances Antineoplastic Agents ; Cannabinoid Receptor Agonists ; Cannabinoids ; Cannabidiol (19GBJ60SN5) ; nabilone (2N4O9L084N) ; Dronabinol (7J8897W37S)
    Language English
    Publishing date 2021-02-01
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2020.35913
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Cannabidiol as a potential treatment for psychosis.

    Davies, Cathy / Bhattacharyya, Sagnik

    Therapeutic advances in psychopharmacology

    2019  Volume 9, Page(s) 2045125319881916

    Abstract: Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treatment of ...

    Abstract Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treatment of psychotic disorders and they remain the mainstay of our treatment arsenal for psychosis. However, traditional antipsychotics are associated with a number of side effects and a significant proportion of patients do not achieve an adequate remission of symptoms. There is therefore a need for novel interventions, particularly those with a non-D2 antagonist mechanism of action. Cannabidiol (CBD), a non-intoxicating constituent of the cannabis plant, has emerged as a potential novel class of antipsychotic with a unique mechanism of action. In this review, we set out the prospects of CBD as a potential novel treatment for psychotic disorders. We first review the evidence from the perspective of preclinical work and human experimental and neuroimaging studies. We then synthesise the current evidence regarding the clinical efficacy of CBD in terms of positive, negative and cognitive symptoms, safety and tolerability, and potential mechanisms by which CBD may have antipsychotic effects.
    Language English
    Publishing date 2019-11-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2646542-5
    ISSN 2045-1261 ; 2045-1253
    ISSN (online) 2045-1261
    ISSN 2045-1253
    DOI 10.1177/2045125319881916
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top